Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 271 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... May 29, 2026 Two Large Studies with New Screening Tests Show Promise for Increasing... March 18, 2024 Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... December 19, 2022 Load more HOT NEWS Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker Making the most of your ‘eureka’ moment: getting from the science... Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... Many Older Adults Screened Unnecessarily for Common Cancers
